UY34527A - ?composiciones, métodos y kits para la preparación de proteínas recombinantes sialiladas?. - Google Patents

?composiciones, métodos y kits para la preparación de proteínas recombinantes sialiladas?.

Info

Publication number
UY34527A
UY34527A UY0001034527A UY34527A UY34527A UY 34527 A UY34527 A UY 34527A UY 0001034527 A UY0001034527 A UY 0001034527A UY 34527 A UY34527 A UY 34527A UY 34527 A UY34527 A UY 34527A
Authority
UY
Uruguay
Prior art keywords
recombining
kits
proteins
compositions
sealed
Prior art date
Application number
UY0001034527A
Other languages
English (en)
Inventor
Barnett Thomas
Original Assignee
Grifols Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Grifols Sa filed Critical Grifols Sa
Publication of UY34527A publication Critical patent/UY34527A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/37—Factors VIII
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45—Transferases (2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1048—Glycosyltransferases (2.4)
    • C12N9/1081—Glycosyltransferases (2.4) transferring other glycosyl groups (2.4.99)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y204/00—Glycosyltransferases (2.4)
    • C12Y204/99—Glycosyltransferases (2.4) transferring other glycosyl groups (2.4.99)
    • C12Y204/99004—Beta-galactoside alpha-2,3-sialyltransferase (2.4.99.4)

Abstract

Procedimiento para alterar un patrón de sialilación de una o más proteínas recombinantes expresadas en una célula, en el que la célula está modificada genéticamente para expresar recombinantemente una a2,3-sialiltransferasa para sialilar la proteína. Este sistema de expresión incrementa la sialilación de la proteína que se expresa, en particular la cantidad de un ácido siálico enlazado por a-2,3 unido a la proteína.
UY0001034527A 2011-12-19 2012-12-19 ?composiciones, métodos y kits para la preparación de proteínas recombinantes sialiladas?. UY34527A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201161577291P 2011-12-19 2011-12-19

Publications (1)

Publication Number Publication Date
UY34527A true UY34527A (es) 2013-07-31

Family

ID=47681979

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001034527A UY34527A (es) 2011-12-19 2012-12-19 ?composiciones, métodos y kits para la preparación de proteínas recombinantes sialiladas?.

Country Status (4)

Country Link
AR (1) AR089324A1 (es)
AU (1) AU2012340501A1 (es)
UY (1) UY34527A (es)
WO (1) WO2013093760A2 (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3889173B1 (en) * 2013-02-15 2023-07-05 Bioverativ Therapeutics Inc. Optimized factor viii gene
US20160130324A1 (en) 2014-10-31 2016-05-12 Shire Human Genetic Therapies, Inc. C1 Inhibitor Fusion Proteins and Uses Thereof
EP3042952A1 (en) 2015-01-07 2016-07-13 CEVEC Pharmaceuticals GmbH O-glycan sialylated recombinant glycoproteins and cell lines for producing the same
EP4089109A3 (en) 2015-05-22 2023-03-01 CSL Behring Lengnau AG Methods for preparing modified von willebrand factor
ES2774011T3 (es) 2015-05-22 2020-07-16 CSL Behring Lengnau AG Polipéptidos del factor de von Willebrand truncado para tratar la hemofilia
BR112018010160A8 (pt) 2015-11-19 2019-02-26 Shire Human Genetic Therapies inibidor da c1 esterase humana recombinante e usos do mesmo
BR112018013861A2 (pt) 2016-01-07 2018-12-18 Csl Behring Recombinant Facility Ag polipeptídeo, complexo, composição farmacêutica, métodos para tratar um distúrbio de coagulação sanguínea, para produzir um polipeptídeo e um dímero de um polipeptídeo, para aumentar a meia vida do fator viii e para aumentar a dimerização do dito polipeptídeo, uso de um polipeptídeo, kit farmacêutico, plasmídeo ou vetor, e, célula hospedeira
DK3411478T3 (da) 2016-02-01 2022-09-12 Bioverativ Therapeutics Inc Optimerede faktor viii-gener
DK3538134T3 (da) 2016-11-11 2022-02-07 CSL Behring Lengnau AG Trunkeret von willebrand-faktor polypeptider til ekstravaskulær administration til behandling eller profylakse af en blodkoagulationsforstyrrelse
AU2017358861B2 (en) 2016-11-11 2022-02-17 CSL Behring Lengnau AG Truncated von Willebrand Factor polypeptides for treating hemophilia
EP3382014A1 (en) * 2017-03-29 2018-10-03 CEVEC Pharmaceuticals GmbH Recombinant glycoproteins with reduced antennary fucosylation
ES2966835T3 (es) 2017-06-22 2024-04-24 CSL Behring Lengnau AG Modulación de la inmunogenicidad del FVIII por VWF truncado
KR20220029733A (ko) 2019-07-04 2022-03-08 체에스엘 베링 렝나우 아게 응고 인자 viii의 시험관내 안정성을 증가시키기 위한 절단된 폰 빌레브란트 인자 (vwf)
WO2021081670A1 (en) * 2019-11-01 2021-05-06 The University Of British Columbia Compositions and methods for sialylated mucin-type o-glycosylation of therapeutic proteins
WO2021094344A1 (en) 2019-11-11 2021-05-20 CSL Behring Lengnau AG Polypeptides for inducing tolerance to factor viii

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4652639A (en) 1982-05-06 1987-03-24 Amgen Manufacture and expression of structural genes
US4511503A (en) 1982-12-22 1985-04-16 Genentech, Inc. Purification and activity assurance of precipitated heterologous proteins
US4965199A (en) 1984-04-20 1990-10-23 Genentech, Inc. Preparation of functional human factor VIII in mammalian cells using methotrexate based selection
US4931373A (en) 1984-05-25 1990-06-05 Zymogenetics, Inc. Stable DNA constructs for expression of α-1 antitrypsin
US5149637A (en) 1987-04-06 1992-09-22 Scripps Clinic & Research Foundation Recombinant Factor VIIIC fragments
US5043429B1 (en) 1987-05-01 1997-10-14 Scripps Research Inst Protein fragments containing factor VIII binding domain of von willebrand factor
US5661008A (en) 1991-03-15 1997-08-26 Kabi Pharmacia Ab Recombinant human factor VIII derivatives
CZ218498A3 (cs) 1996-01-23 1998-12-16 Rapigene, Inc. Způsoby a kompozice pro stanovení sekvence molekul nukleových kyselin
US6613508B1 (en) 1996-01-23 2003-09-02 Qiagen Genomics, Inc. Methods and compositions for analyzing nucleic acid molecules utilizing sizing techniques
US6312893B1 (en) 1996-01-23 2001-11-06 Qiagen Genomics, Inc. Methods and compositions for determining the sequence of nucleic acid molecules
AT403765B (de) 1996-04-12 1998-05-25 Immuno Ag Verfahren zur herstellung einer präparation enthaltend einen hochgereinigten komplex
US6120460A (en) 1996-09-04 2000-09-19 Abreu; Marcio Marc Method and apparatus for signal acquisition, processing and transmission for evaluation of bodily functions
JP2001511362A (ja) 1997-07-22 2001-08-14 ラピジーン，インコーポレイテッド Ｍｓにより配列決定データを相関させるコンピュータ方法およびシステム
SI1161548T2 (sl) 1999-04-15 2010-02-26 Crucell Holland Bv Priprava rekombinantnega proteina v humani celici z uporabo sekvenc, ki kodirajo adenovirusni E1 protein
US20060099685A1 (en) * 1999-04-15 2006-05-11 Yallop Christopher A Recombinant expression of factor VIII in human cells
US7297680B2 (en) * 1999-04-15 2007-11-20 Crucell Holland B.V. Compositions of erythropoietin isoforms comprising Lewis-X structures and high sialic acid content
US6664112B2 (en) 2000-06-02 2003-12-16 Blue Heron Biotechnology, Inc. Methods for improving the sequence fidelity of synthetic double-stranded oligonucleotides
WO2003054232A2 (en) 2001-12-13 2003-07-03 Blue Heron Biotechnology, Inc. Methods for removal of double-stranded oligonucleotides containing sequence errors using mismatch recognition proteins
US7642078B2 (en) 2005-12-28 2010-01-05 Crucell Holland B.V. Methods to obtain recombinant proteins with increased sialylation from cells that express adenovirus E1A protein, and proteins obtained thereby
TWI488640B (zh) * 2008-04-16 2015-06-21 Ferring Int Ct Sa 藥學製劑
TWI604850B (zh) * 2009-10-05 2017-11-11 菲瑞茵國際中心股份有限公司 藥學製劑
US20110086362A1 (en) 2009-10-09 2011-04-14 Massachusetts Institute Of Technology High-Throughput Method for Quantifying Sialylation of Glycoproteins

Also Published As

Publication number Publication date
AU2012340501A1 (en) 2013-07-11
WO2013093760A3 (en) 2013-11-14
WO2013093760A2 (en) 2013-06-27
AR089324A1 (es) 2014-08-13

Similar Documents

Publication Publication Date Title
UY34527A (es) ?composiciones, métodos y kits para la preparación de proteínas recombinantes sialiladas?.
CR20140212A (es) Anticuerpos anti-htra1 y métodos de uso
TR201909788T4 (tr) C4-monometil triterpenoid türevleri ve bunların kullanım yöntemleri.
CR20140529A (es) Anticuerpos e inmunoconjugados contra ly6e y métodos de uso
UY34885A (es) Proteínas de unión anti-mesotelina
CR20150046A (es) Anticuerpos anti-cd79b e inmunoconjugados
MX2013008390A (es) Preparacion de estructuras de metal-triazolato.
EA201590993A1 (ru) Гетеродимерные иммуноглобулины
EA201591474A1 (ru) Модуляторы метил-модифицирующих ферментов, композиции и их применение
EA201391274A1 (ru) Аминохинолины в качестве ингибиторов киназ
CR20150247A (es) Anticuerpos de antihemaglutinina y métodos de uso
TN2013000378A1 (en) Anti - sclerostin antibody crystals and formulations thereof
CL2016000344A1 (es) Procedimiento de preparación de 5-fluoro-1h-pirazolopiridinas sustituidas
UY34763A (es) Inhibidores de la agregación plaquetaria
UY34602A (es) ?Derivados de bencimidazolil- e imidazopiridinil-metilamina?
EA201491811A1 (ru) АНТИ-LgR5 АНТИТЕЛА И ИММУНОКОНЪЮГАТЫ
MX342240B (es) Anticuerpos anti-fgfr4 y metodos de uso.
EA201491224A1 (ru) Анти-псф-тау-антитела и их применение
UY34254A (es) Proteínas y péptidos modificados.
AU2013225533A8 (en) Amido spirocyclic amide and sulfonamide derivatives
MX2014002053A (es) Anticuerpos anti -mcsp y metodos de uso.
EA201491357A1 (ru) Анти-lrp5 антитела и способы их применения
EA202091397A1 (ru) Бензохинолоновые ингибиторы vmat2
TR201909271T4 (tr) Testosteron formülasyonları.
EA201290642A1 (ru) Соединения и способы

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20201020